Taisho Pharmaceutical Statistics
Share Statistics
Taisho Pharmaceutical has 315.54M
shares outstanding. The number of shares has increased by 0%
in one year.
| Shares Outstanding | 315.54M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 5.95 and the forward
PE ratio is null.
Taisho Pharmaceutical's PEG ratio is
0.14.
| PE Ratio | 5.95 |
| Forward PE | n/a |
| PS Ratio | 0.37 |
| Forward PS | n/a |
| PB Ratio | 0.14 |
| P/FCF Ratio | -12.01 |
| PEG Ratio | 0.14 |
Financial Ratio HistoryEnterprise Valuation
Taisho Pharmaceutical has an Enterprise Value (EV) of -140.43B.
| EV / Sales | -0.47 |
| EV / EBITDA | -2.59 |
| EV / EBIT | -3.43 |
| EV / FCF | 14.93 |
Financial Position
The company has a current ratio of 5.09,
with a Debt / Equity ratio of 0.
| Current Ratio | 5.09 |
| Quick Ratio | 4.37 |
| Debt / Equity | 0 |
| Debt / EBITDA | 0.05 |
| Debt / FCF | -0.28 |
| Interest Coverage | 136.2 |
Financial Efficiency
Return on Equity is 2.42% and Return on Invested Capital is 2.11%.
| Return on Equity | 2.42% |
| Return on Assets | 2.02% |
| Return on Invested Capital | 2.11% |
| Revenue Per Employee | $34,310,223.13 |
| Profits Per Employee | $2,162,682.15 |
| Employee Count | 8,784 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 2.32 |
Taxes
| Income Tax | 8.2B |
| Effective Tax Rate | 27.78% |
Stock Price Statistics
The stock price has increased by 16.67% in the
last 52 weeks. The beta is 0.44, so Taisho Pharmaceutical's
price volatility has been higher than the market average.
| Beta | 0.44 |
| 52-Week Price Change | 16.67% |
| 50-Day Moving Average | 13.58 |
| 200-Day Moving Average | 12.03 |
| Relative Strength Index (RSI) | 27.25 |
| Average Volume (20 Days) | 202 |
Income Statement
In the last 12 months, Taisho Pharmaceutical had revenue of 301.38B
and earned 19B
in profits. Earnings per share was 231.72.
| Revenue | 301.38B |
| Gross Profit | 177.85B |
| Operating Income | 23.02B |
| Net Income | 19B |
| EBITDA | 54.31B |
| EBIT | 29.67B |
| Earnings Per Share (EPS) | 231.72 |
Full Income StatementBalance Sheet
The company has 255.97B in cash and 2.59B in
debt, giving a net cash position of 253.38B.
| Cash & Cash Equivalents | 255.97B |
| Total Debt | 2.59B |
| Net Cash | 253.38B |
| Retained Earnings | 713.78B |
| Total Assets | 1,005.5B |
| Working Capital | 335.95B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 40.97B
and capital expenditures -50.38B, giving a free cash flow of -9.41B.
| Operating Cash Flow | 40.97B |
| Capital Expenditures | -50.38B |
| Free Cash Flow | -9.41B |
| FCF Per Share | -114.74 |
Full Cash Flow StatementMargins
Gross margin is 59.01%, with operating and profit margins of 7.64% and 6.3%.
| Gross Margin | 59.01% |
| Operating Margin | 7.64% |
| Pretax Margin | 9.79% |
| Profit Margin | 6.3% |
| EBITDA Margin | 18.02% |
| EBIT Margin | 7.64% |
| FCF Margin | -3.12% |
